Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat + bortezomib + dexamethasone induction for transplant-eligible untreated multiple myeloma
2011-005847-29Phase 2Terminated
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Complete response rate. Started Mar 2012; status: terminated.
02
Drugs
panobinostatbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2011-005847-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005847-29.